GlassScriptPhysician profile
Alicia Williams
NPI 1629733290
$2,896.29
in general payments reported to CMS, 2019-2025
21 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $579 · 2023: $916 · 2024: $1,258 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.18 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $605.24 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $349.31 | 2022-2024 | Brilinta, Andexxa, Farxiga |
| Janssen Pharmaceuticals, INC | $327.38 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.37 | 2022-2025 | Jardiance |
| Amgen INC. | $210.17 | 2022-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $201.47 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $185.49 | 2023 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $141.76 | 2022-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $117.26 | 2024-2025 | Verquvo |
| Otsuka America Pharmaceutical, INC. | $84.59 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $74.77 | 2023-2024 | |
| Abiomed | $71.95 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $67.36 | 2023-2024 | Inpefa |
| Irhythm Technologies, INC. | $60.81 | 2024 | Zio Xt Patch, Zio Monitor |
| Pfizer INC. | $44.91 | 2022-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $37.08 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $17.66 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $17.10 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $16.61 | 2023 | Nexletol |
| Alnylam Pharmaceuticals INC. | $16.20 | 2024 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $13.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.